Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017

Executive Summary

Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.

Advertisement

Related Content

Gene Therapy Guidances Will Focus On Specific Diseases, Gottlieb Says
Priority Review Designations In US: Third Quarter Spike Continues In 2017
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel